A Comparison of Citalopram and Paroxetine in the Treatment of Panic Disorder: A Randomized, Single-Blind Study

Background: Serotonin Selective Re-uptake Inhibitors (SSRIs) are the drugs of choice for treating panic disorder (PD). In vitro studies have shown different pharmacodynamic profiles for SSRIs, but their clinical relevance is still unknown. Paroxetine, the SSRI with the strongest serotonergic effect, also shows significant cholinergic and noradrenergic activities. In this class of drugs, citalopram is the most selective for serotonin. We compared these two drugs and their effectiveness and tolerability in a sample of patients with PD in a two-month treatment course. Method: Fifty-eight patients with PD were randomly assigned to either the paroxetine or the citalopram treatment group in a single-blind, randomized design. Each patient was assessed at days 0, 7 and 60 by the Panic Associated Symptoms Scale (PASS), the Sheehan Disability Scale (SDS) and the Fear Questionnaire (FQ). Primary outcome measures were the percentage of patients free of panic attacks, anticipatory anxiety and phobic avoidance in the last week of the trial and the percentage of good responders, as defined by a reduction of at least 50 % from baseline of both PASS and SDS global scores at day 60. Results: At day 60, 86 % of patients receiving citalopram and 84 % of those receiving paroxetine responded well to treatment. No significant differences between the two drugs were found. Both were well tolerated, although sexual side effects and weight gain were frequent. Anticipatory anxiety decreased significantly after the first week of treatment, and no initial worsening in the panic attacks was observed. Conclusion: Paroxetine and citalopram show similar anti-panic properties and a good tolerability profile. Our results support evidence that the serotonergic system plays a significant role in the anti-panic properties of these two SSRIs.

References

• 1 Argyle N, Deltito J, Allerup P, Nutziger D, Rasmussen S, Ayuso J L, Bech P. The Panic-Associated Symptoms Scale: measuring the severity of panic disorder.  Acta Psychiatrica Scandinavica. 1991;  83 20-26
• 2 Ballenger J C, Wheadon D E, Steiner M, Bushnell W, Gergel I P. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder.  American Journal of Psychiatry. 1998;  155 36-42
• 3 Bertani A, Perna G, Politi E, Bellodi L. Citalopram and panic disorder.  Depression and Anxiety. 1996;  4 253
• 4 Bertani A, Perna G, Caldirola D, Arancio C, Bellodi L. Pharmacologic effect of paroxetine, sertraline and imipramine on reactivity to the 35 % CO₂ challenge: a double blind, random, placebo controlled study.  Journal of Clinical Psychopharmacology. 1997;  17 97-101
• 5 Burnham D B, Steiner M, Gergel I P, Oakes R, Bailer D C, Wheadon D E. Paroxetine long term safety and efficacy in panic disorder and prevention of relapse: a double-blind study. Presented at the American College of Neuropsychopharmacology (ACNP) San Juan, Puertorico; 1995
• 6 Cassano G B, Petracca A, Perugi G, Nisita C, Musetti L, Mengali F, McNair D M. Clomipramine for Panic Disorder: I. The first 10 weeks of a long-term comparison with imipramine.  Journal of Affective Disorders. 1988;  14 123-127
• 7 Den Boer J A, Westenberg H G M. Effect of serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline.  International Clinical Psychopharmacology. 1988;  3 59-74
• 8 Fawcett J. Suicide risk factors in depressive disorders and in panic disorder.  Journal of Clinical Psychiatry. 1992;  53 9-13
• 9 Hoehn-Saric R, McLeod D R, Hispley P A. Effect of fluvoxamine on panic disorder.  Journal of Clinical Psychopharmacology. 1993;  13 321-326
• 10 Humble M, Wisted B. Serotonin, panic disorder and agoraphobia: short term and long term efficacy in panic disorder.  lnternational Clinical Psychopharmacology. 1992;  6 21-39
• 11 Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs).  Internations Clinical Psychopharmacology. 1994;  9 19-26
• 12 Hyttel J, Arnt J, Sanchez C. The pharmacology of citalopram.  Reviews in Contemporary Pharmacotherapy. 1995;  6 271-285
• 13 Johnson A M. Paroxetine: a pharmacological review.  International Clinical Psychopharmacology. 1992;  4 15-24
• 14 Kahn R S, Wetzler S, van Praag H M, Asnis G M, Strauman T. Behavioral indications for serotonin receptor hypersensitivity in panic disorder.  Psychiatry Research. 1988;  25 101-104
• 15 Kent J M, Coplan J D, Martinez J, Karmally W, Papp L A, Gorman J M. Ventilatory effects of tryptophan depletion in panic disorder: a preliminary report.  Psychiatry Research. 1996;  64 83-90
• 16 Klaasen T, Klumperbeek J, Jeutz N E, van Praag H M, Griez E. Effects of tryptophan depletion on anxiety and on panic provoked by carbon dioxide challenge.  Psychiatry Research. 1998;  77 167-174
• 17 Klein D F. Delineation of two-responsive anxiety syndromes.  Psychopharmacologia. 1964;  5 397-408
• 18 Klein D F. False suffocation alarm, spontaneous panic, and related condition.  Archives of General Psychiatry. 1993;  50 306-317
• 19 Lecrubier Y, Bakker A, Dunbar G, Judge R. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder.  Acta Psychiatrica Scandinavica. 1997 a;  95 145-152
• 20 Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder.  Acta Psychiatrica Scandinavica. 1997 b;  95 153-160
• 21 Leinonen E, Lepola U, Tutonen J, Wade A G, Lehto H. Citalopram controls phobic symptoms in patients with panic disorder: randomized, controlled trial.  Journal of Psychiatry and Neuroscience. 2000;  25 24-32
• 22 Leon A C, Shear M K, Portera L, Klerman G L. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale.  Social Psychiatry and Psychiatric Epidemiology. 1992;  27 78-82
• 23 Lepola U, Leinonen E, Turtonen J. The effect of citalopram in panic disorder and agoraphobia: a pilot study.  Nordic Journal of Psychiatry. 1994;  48 13-17
• 24 Lepola U M, Wade A G, Leinonen E V, Koponen H J, Frazer J, Sjodin I, Penttinen J T, Pedersen T, Lehto H J. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder.  Journal of Clinical Psychiatry. 1998;  59 528-534
• 25 Liebowitz M R, Gorman J M. Panic and anxiety disorders. Ed Cavenar JO Philadelphia; In: Psychiatry Vol. 1. Chap. 32, JB Lippincott Company 1-13
• 26 Lundberg D B A, Mueller R A, Breese G R. An evaluation of the mechanism by which serotonergic activation depresses respiration.  Journal of Pharmacology and Experimental Therapy. 1980;  212 397-404
• 27 Marks I M, Mathews A M. Brief standard self-rating for phobic patients.  Behaviour Research and Therapy. 1979;  17 263-267
• 28 Modigh K, Wetenberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder. A placebo-controlled trial.  Journal of Clinical Psychopharmacology. 1992;  12 251-261
• 29 National Institute of Mental Health Research (NIMH), Department of Education and Welfare .ECDEU Assessment Manual . Eds Levin J and Guy W Rockville, MD, National Institute of Mental Health 1976
• 30 Noyes R. Suicide in panic disorder: a review.  Psychiatry Medicine. 1990;  8 41-66
• 31 Nutt D. The role of SSRIs in anxiety disorders.  European Neuropsychopharmacology. 1995;  5 260-261
• 32 Olson E B, Dempsey J A, McCrimmon D R. Serotonin and the control of ventilation in the awake rat.  Journal of Clinical Investigation. 1979;  64 689-693
• 33 Oehrberg S, Christiansen P E, Benke K. Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo controlled study.  British Journal of Psychiatry. 1995;  167 374-379
• 34 Perna G, Bertani A, Gabriele A, Politi E, Bellodi L. Modification of 35 % CO₂ hypersensitivity across one week of treatment with clomipramine and fluvoxamine: a double blind, randomized, placebo controlled study.  Journal of Clinical Psychopharmacology. 1997;  17 173-178
• 35 Price L H, Goddhard A W, Barr L. Pharmacologic challenges in anxiety disorders. Eds Bloom FE, Kupfer DJ Psychopharmacology: The fourth generation of progress. Raven Press, New York 1311-1325
• 36 Regier D A, Narrow W, Rae D S. The epidemiology of anxiety disorders: the epidemiological catchment area (ECA) experience.  Journal of Psychiatric Research. 1990;  24 3-4
• 37 Sasson Y, Iancu I, Fux M, Taub M, Dannon P N, Zohar J. A double-blind, cross-over comparison of clomipramine and desipramine in the treatment of panic disorder.  European Neuropsychopharmacology. 1999;  9 191-196
• 38 Sheehan D V, Ballenger J C, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms.  Archives of General Psychiatry. 1980;  37 51-59
• 39 Sheevan D V, Lecrubier Y, Janavs J, Knapp E, Weiler E, Bonora P, Sheedan M, Amorim P, Baker R, Sheehan K H, Lepine J P. Mini International Neuropsychiatric Interview. MINI, Paris/Tampa 1994
• 40 Steiner M, Oakes R, Gergel I P, Burnham D B, Wheadon D E. A fixed dose study of paroxetine and placebo in the treatment in panic disorder. Presented at the 148th Annual Meeting of the American Psychiatric Association, Miami, Florida 1995
• 41 Targum S D. Panic attacks frequency and vulnerability to anxiogenic challenge studies.  Psychiatry Research. 1991;  36 75-83
• 42 Targum S D, Marshall L E. Fenfluramine provocation of anxiety in patients with panic disorder.  Psychiatry Research. 1989;  28 295-306
• 43 Tesar G E, Rosenbaum J F, Pollack M H, Otto M W, Sachs G S, Herman J B, Cohen L S, Spier S A. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder.  Journal of Clinical Psychiatry. 1991;  52 69-76
• 44 Thomas D R, Nelson D R, Johnson A M. Biochemical effects off the antidepressant paroxetine, a specific 5-hydroxytriptamine uptake inhibitor.  Psychopharmacology. 1987;  93 193-200
• 45 Wade A G, Lepola U, Koponen H J, Pedersen V, Pedersen T. The effect of citalopram in panic disorder.  British Journal of Psychiatry. 1997;  170 549-553
• 46 Wittchen H U. Natural course and spontaneous remissions of untreated anxiety disorders: results of the Munich Follow-up Study.  Eds Hand I, Wittchen HU Panic and Phobias: treatments and variables affecting course and outcome. 1988 SpringerVerlag, NewYork 3-17
• 47 Yeregani V K, Jampala V C, Sobelewski E, Igel G. Effects of paroxetine on hearth period variability in patients with panic disorder: a study of holter ECG records.  Neuropsychobiology. 1999;  40 124-128
• 48 Zitrin Z M, Klein D F, Woerner M G, Ross D C. Treatment of phobias I. Comparison of imipramine hydrochloridate and placebo.  Archives General Psychiatry. 1983;  40 125-138